Open AccessAtypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab
Author(s) -
Aude Servais,
Nadège Devillard,
Véronique FrémeauxBacchi,
Aurélie Hummel,
Laurent Salomon,
Cécile ContinBordes,
H. Gomer,
Christophe Legendre,
Yahsou Delmas
Publication year - 2016
Publication title -
nephrology dialysis transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.654
H-Index - 168
eISSN - 1460-2385
pISSN - 0931-0509
DOI - 10.1093/ndt/gfw314
Subject(s) - eculizumab , medicine , pregnancy , atypical hemolytic uremic syndrome , gestation , obstetrics , pediatrics , gastroenterology , complement system , immunology , antibody , genetics , biology
A therapeutic strategy based on complement blockade by eculizumab is widely used to treat atypical haemolytic uraemic syndrome (aHUS). Recent data are available on the administration of eculizumab during pregnancy in patients treated for paroxysmal nocturnal haemoglobinuria but there are very few data for aHUS patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom